183 related articles for article (PubMed ID: 27764799)
1. Polymeric nanoparticle-docetaxel for the treatment of advanced solid tumors: phase I clinical trial and preclinical data from an orthotopic pancreatic cancer model.
Song SY; Kim KP; Jeong SY; Park J; Park J; Jung J; Chung HK; Lee SW; Seo MH; Lee JS; Jung KH; Choi EK
Oncotarget; 2016 Nov; 7(47):77348-77357. PubMed ID: 27764799
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel-encapsulating small-sized polymeric micelles with higher permeability and its efficacy on the orthotopic transplantation model of pancreatic ductal adenocarcinoma.
Li Y; Li P; Jin M; Jiang C; Gao Z
Int J Mol Sci; 2014 Dec; 15(12):23571-88. PubMed ID: 25526569
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of taxane-binding peptide-modified polymeric micelles loaded with docetaxel in an orthotopic breast cancer mouse model.
Logie J; Ganesh AN; Aman AM; Al-Awar RS; Shoichet MS
Biomaterials; 2017 Apr; 123():39-47. PubMed ID: 28161682
[TBL] [Abstract][Full Text] [Related]
4. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors.
Iqbal S; Lenz HJ; Gandara DR; Shibata SI; Groshen S; Synold TW; Newman EM
Cancer Chemother Pharmacol; 2013 Jul; 72(1):85-91. PubMed ID: 23712328
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin.
Kim H; Lee Y; Lee IH; Kim S; Kim D; Saw PE; Lee J; Choi M; Kim YC; Jon S
J Control Release; 2014 Mar; 178():118-24. PubMed ID: 24462899
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
9. ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors.
Luke JJ; LoRusso P; Shapiro GI; Krivoshik A; Schuster R; Yamazaki T; Arai Y; Fakhoury A; Dmuchowski C; Infante JR
Cancer Chemother Pharmacol; 2016 Mar; 77(3):549-58. PubMed ID: 26811179
[TBL] [Abstract][Full Text] [Related]
10. Coadministration of Polymeric Conjugates of Docetaxel and Cyclopamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis.
Almawash SA; Mondal G; Mahato RI
Pharm Res; 2018 Jan; 35(1):17. PubMed ID: 29305793
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
Mahalingam D; Nemunaitis JJ; Malik L; Sarantopoulos J; Weitman S; Sankhala K; Hart J; Kousba A; Gallegos NS; Anderson G; Charles J; Rogers JM; Senzer NN; Mita AC
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1241-50. PubMed ID: 25304209
[TBL] [Abstract][Full Text] [Related]
12. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles.
Hwang HY; Kim IS; Kwon IC; Kim YH
J Control Release; 2008 May; 128(1):23-31. PubMed ID: 18374444
[TBL] [Abstract][Full Text] [Related]
13. A novel mixed micelle gel with thermo-sensitive property for the local delivery of docetaxel.
Yang Y; Wang J; Zhang X; Lu W; Zhang Q
J Control Release; 2009 Apr; 135(2):175-82. PubMed ID: 19331864
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models.
Ernsting MJ; Tang WL; MacCallum NW; Li SD
Biomaterials; 2012 Feb; 33(5):1445-54. PubMed ID: 22079003
[TBL] [Abstract][Full Text] [Related]
15. Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer.
He C; Cai P; Li J; Zhang T; Lin L; Abbasi AZ; Henderson JT; Rauth AM; Wu XY
J Control Release; 2017 Jan; 246():98-109. PubMed ID: 28017889
[TBL] [Abstract][Full Text] [Related]
16. NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo.
Harada M; Iwata C; Saito H; Ishii K; Hayashi T; Yashiro M; Hirakawa K; Miyazono K; Kato Y; Kano MR
Int J Nanomedicine; 2012; 7():2713-27. PubMed ID: 22745540
[TBL] [Abstract][Full Text] [Related]
17. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle.
Ernsting MJ; Hoang B; Lohse I; Undzys E; Cao P; Do T; Gill B; Pintilie M; Hedley D; Li SD
J Control Release; 2015 May; 206():122-30. PubMed ID: 25804872
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer.
Mugabe C; Matsui Y; So AI; Gleave ME; Baker JH; Minchinton AI; Manisali I; Liggins R; Brooks DE; Burt HM
Clin Cancer Res; 2011 May; 17(9):2788-98. PubMed ID: 21357680
[TBL] [Abstract][Full Text] [Related]
19. Arginine-stabilized mPEG-PDLLA (50/50) polymeric micelles of docetaxel by electrostatic mechanism for tumor-targeted delivery.
Shi J; Zhang J; Shen Y; Tang L; Zhao J; Tu J; Tian Y; Feng Y
Drug Deliv; 2015 Feb; 22(2):168-81. PubMed ID: 24215124
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration.
Lee E; Kim H; Lee IH; Jon S
J Control Release; 2009 Dec; 140(2):79-85. PubMed ID: 19712714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
